Pediatric Lung Transplant Outcomes Based on Immunosuppressive Regimen at Discharge: Retrospective Cohort Study Using Real-World Evidence From the US Scientific Registry of Transplant Recipients
Transplantation Proceedings · 2023
DOI: 10.1016/j.transproceed.2023.05.022 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Transplantation Proceedings, 2023. Verfasst von Jay Erdman und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical Specialties Therapeutic Area, Astellas Pharma, Inc, Northbrook, Illinois. Hauptthemen laut MEDLINE: Kidney Transplantation, Lung Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Astellas Pharma US.
Abstract (Originalsprache)
BACKGROUND: This retrospective analysis of the US Scientific Registry of Transplant Recipients was undertaken to obtain real-world evidence concerning the efficacy and safety of tacrolimus-based immunosuppression in pediatric lung transplant recipients to support a supplemental New Drug Application. METHODS: Overall, 725 pediatric recipients of a primary deceased-donor lung transplant between January 1, 1999, and December 31, 2017, were followed for up to 3 years post-transplant based on an immunosuppressive regimen at hospital discharge: immediate-release tacrolimus (TAC)+mycophenolate mofetil (MMF), TAC+azathioprine (AZA), cyclosporine (CsA)+MMF, or CsA+AZA. The primary outcome was the composite endpoint of graft failure or death (all-cause) at 1 year post-transplant, calculated by Kaplan-Meier analysis. RESULTS: The use of TAC+MMF increased over time. During 2010 to 2017, 91.7% of pediatric lung transplant recipients were receiving TAC+MMF at the time of discharge. The proportion of recipients continuing their discharge regimen at 1 year post-transplant was 83.7% with TAC+MMF and 40.4% to 59.7% with the other regimens. Cumulative incidence of the composite endpoint of graft failure or death at 1 year post-transplant was 7.7% with TAC+MMF, 13.9% with TAC+AZA, 8.9% with CsA+MMF, and 9.1% with CsA+AZA. There was no significant difference in the risk of graft failure or death at 1 year post-transplant between groups from 1999 to 2005 (the only era when adequate numbers on each regimen allowed statistical comparison). No increase in hospitalization for infection or malignancy was seen with TAC+MMF. CONCLUSION: The real-world evidence from the US database of transplant recipients supported the Food and Drug Administration's approval of tacrolimus-based maintenance immunosuppression in pediatric lung transplant recipients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical Specialties Therapeutic Area, Astellas Pharma, Inc, Northbrook, Illinois.
- Real World Data & Evidence, Advanced Informatics and Analytics, Astellas Pharma Europe BV, Leiden, Netherlands.
- Real World Evidence-Americas, Advanced Informatics and Analytics, Astellas Pharma, Inc, Northbrook, Illinois.
- Data Science, Astellas Pharma, Inc, Northbrook, Illinois.
- Global Medical Lead, Medical Specialties, Astellas Pharma, Inc, Northbrook, Illinois.
- Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, Minnesota.
Förderung
- Astellas Pharma US
Zitieren
APA
Erdman, J., Wolfram, J., Nimke, D., Croy, R., Wang, X., Weaver, T., Schladt, D., & Fitzsimmons, W. E. (2023). Pediatric Lung Transplant Outcomes Based on Immunosuppressive Regimen at Discharge: Retrospective Cohort Study Using Real-World Evidence From the US Scientific Registry of Transplant Recipients. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2023.05.022
Vancouver
Erdman J, Wolfram J, Nimke D, Croy R, Wang X, Weaver T, et al. Pediatric Lung Transplant Outcomes Based on Immunosuppressive Regimen at Discharge: Retrospective Cohort Study Using Real-World Evidence From the US Scientific Registry of Transplant Recipients. Transplantation Proceedings. 2023. doi:10.1016/j.transproceed.2023.05.022
BibTeX
@article{Erdman2023,
author = {Erdman, Jay and Wolfram, Josephine and Nimke, David and Croy, Richard and Wang, Xuegong and Weaver, Tim and Schladt, David and Fitzsimmons, William E},
title = {Pediatric Lung Transplant Outcomes Based on Immunosuppressive Regimen at Discharge: Retrospective Cohort Study Using Real-World Evidence From the US Scientific Registry of Transplant Recipients},
journal = {Transplantation Proceedings},
year = {2023},
doi = {10.1016/j.transproceed.2023.05.022}
}
EUVIMED